US 11028388
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
granted A61KA61K38/465A61K47/26
Quick answer
US patent 11028388 (CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa) held by Editas Medicine, Inc. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K38/465, A61K47/26